Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILs in CSCC and MCC
NCT07288073Phase 2Recruiting
- Start
- Feb 2026
- Primary completion
- Sep 2028
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
A Phase 2 trial of LN-145 in cutaneous squamous cell carcinoma (cSCC), Merkel cell carcinoma (MCC). Started Feb 2026; status: recruiting.
02
Drugs
LN-145
03
Conditions
cutaneous squamous cell carcinoma (cSCC)Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT07288073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288073.